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BIOAVAILABILITY AND CV COMPONENT COMPARISON IN A CROSSOVER 
Abstract 
Zhiming Wang, Vince A. Uthoff 
QuintileslInnovex 
11250 Corporate Ave 
Lenexa, KS 66219 
Two medication formulations are compared using noncompartmental pharmacokinetic (PK) 
variables. However, more than the ratio of mean effects is of interest. A difference in 
formulation coeficients of varication (CV), within- or between-subject, is sought. The 
experimental design chosen is a 2 sequence crossover design of the form ABBA and BAAB, 
where A and B are two medication formulations. A mixed linear model is defined that contains 
random effects for subjects and for subject by formulation interactions. The model has fixed 
effects for the average formulation effects and period effects. The 2 formulations are assumed to 
have different error terms. The average formulation effect ratios and within-subject CVs may be 
compared by usual methods. An approximate Z-statistic is computed to compare the between-
subject CV s. This statistic assumes a correlation of the 2 between-subject CV estimates. In 
addition, a tractable variance ratio is defined to indicate the extent to which the average effects 
ratio is applicable to each subject. 
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1. Introduction 
In testing for bioequivalence, the focus is usually on showing that the average areas under the 
blood level curve (AUe) of two formulations differ by no more than 20%. Little attention is 
given to the variability of the AUe. Usually variances are assumed to be equal. It is also 
standard practice to use a crossover design because crossover designs require fewer subjects and 
carryover effects have not been a major problem in bioequivalence studies. 
If, however, the original formulation has shown a large within- and between-subject variability, it 
might be of interest to see if the new formulation might not produce a smaller variation. Thus, 
the estimation and testing of variances can be of as much interest as can be the mean effects. 
A second assumption usually made is that the average bioequivalence is applicable to each and 
every patient who takes the drug. That is, it is assumed that the test formulation cannot be >20% 
more bioavailable in one patient while the standard formulation is >20% more bioavailable in a 
second patient. 
We have data from a 4-period, 2-sequence crossover design of the form ABBA and BAAB, 
where A and B are two medication formulations. We are interested in estimating and testing the 
between-subject variance component, the within-subject variance component, the average 
bioavailability and to provide some kind of assessment of the extent to which the average 
bioavailability is applicable to each and every patient. This was also a compound for which the 
standard formulation had shown both a large within- and between-subject variance components 
in previous pharmacokinetic studies. 
Most of what was requested was fairly straight forward. However, the testing of the between-
subject variance component presented a challenge. Most linear models for this kind of a design 
assume a constant between-subject variance component called, "the subject effect." Since the 
design is a crossover, any two estimates of the between-subject variance components are 
correlated. In most tests for variance components, the components are assumed to be 
independent and this cannot hold if 2 different between-subject variance components are 
estimated from the same subjects. 
A second challenge was posed by determining how to best define an index of the degree to which 
the average bioavailability is applicable to each patient. 
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2. Variance Component Analysis of PK Parameters 
Let treatment A be a capsule and treatment B be a tablet. Each subject received 2 treatments in 4 
different periods depending on his assigned treatment sequence. A subject assigned to sequence 
1 received A, B, B, A at period 1,2,3,4, respectively. A sequence 2 subject received B, A, A, 
B. 
Let 
S - N(O, 0/) be the subject effect, 
TSA - N(O, OA2) be the treatment A by subject interaction, 
TSB - N(O, OBZ) be the treatment B by subject interaction, 
ESi - N(O, 0/) be the within-subject error for treatment A, 
l1si - N(O, 0I1Z) be the within-subject error for treatment B. 
Then, for a subject in sequence ABBA, the linear models for the observation on each subject at 





YSll = 11 + S + TSA + 1'A + TI j + ESj ' 
YS12= 11 + S + TSB + 1'B + TIz + l1sl' 
YS13= 11 + S + TSB + 1'B + TI3 + l1sz, 
YSI4= 11 + S + TSA + 1'A + TI4 + ES2' 






YSZI = 11 + S + TSB + 1'B + TIl + l1sl' 
Yszz= 11 + S + TSA + 1'A + TIz + ESI ' 
YSZ3= 11 + S + TSA + 1'A + TI3 + ES2' 
YS24 = 11 + S + TSB + 1'B + TI4 + l1sz· 
In the models above, 11, 1'A' 1'B' TIl' TIz, TI3, and TI4 are fixed effects. These denote the intercept, 
fixed treatment effects and fixed period effects. It is assumed that NI subjects are assigned to 
sequence 1 and Nz subjects are assigned to sequence 2 and N = N j + N2. 
Note that the fixed period effects could be made sequence dependent without changing the 
results which follow. 
For sequence ABBA, let 
ZSI = (YSll + YS14)/2 = 11 + S + TSA + 1'A + (TIl + TI4)/2 + (Esl + Ed/2, 
Zsz = (YSIZ + YS13)/2 = 11 + S + TSB + 1'B + (TI2 + TI 3)/2 + (l1s1 + lldl2, 
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ZS3 = (YSll - YSI4)12 = eltl - TI4)12 + (ESI - ES2)/2, 
ZS3 = (YS12 - YS13)/2 = (TI2 - TI3)/2 + (11s1 -11s2)12, 
for S=1, ... , N1• 
Similarly, for sequence BAAB, let 
W SI = (YS22 + YS23)12 = f-l + S + TSA + 't"A + (TI2 + TI3)/2 + (ESI + EsI )/2, 
W S2 = (YS21 + YS24)/2 = f-l + S + TSB + 't"B + (TIl + TI4)12 + (11s1 + 11sl)l2, 
WS3 = (YS22 - YS23)12 = (TI2 - TI3)12 + (Esl - EsI)I2, 
W S4 = (YS21 - YS24)12 = (TIl - TI4)12 + (11s1 -11sl)l2· 
for S = NI +1, ... , NI + N2. 
Let Zs= (ZSI' ZS2' ZS3' ZS4)', then the random vectors Zs' S=1, ... , N have 
and covariance matrix 
Cov(Zs) 
't" A +( TIl +TI4)/2 
't" B +( TI2 +TI3)/2 
(TI! -TI4)12 
(TI2 -TI3)/2 
2 2 2 2 
(JS+(JA +(Ji2 (Js 








0 2 (JTJ/2 
Similarly, let Ws= (WSJ ' W S2' W S3 ' W S4)" then the random vectors Ws , S = N J +1, ... , N] + N2 
have different means but the same covariance matrix as Zs, S=1, ... , N. 
Let 
A = L (Zs-Z)(Zs-Z)/, B = L (Ws- W)(Ws - W)/ , 
seq=! seq=2 
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where 
By Corollary 7.2.1 of Anderson (1958), A is a Wishart Matrix with df = N 1 -1 and B is also a 
Wishart Matrix with df = N2 -1. 
Let C = A + B = (Ci)4x4 and denote I = (aij )4x4 = Cov(Zs). Then by Theorem 7.3. of Anderson 
(1958), C is a Wishart Matrix with degree of freedom n = N-2 and covariance matrix I. That is, 
C - W(I. n). 
B(D) = n [(a 2 + a 2 + a 2/2) - (a 2 + a 2 + a 2/2 )- a 2/2 + a 2/2 ] = n(a 2 - a 2) and SA € S B 1] € 1] A B' 
Since Var(C.) = 2na.2 and Cov(C. C·) = n(a··a· + a··a··) = 2na· 2 by page 161 of Anderson 11 11 11' JJ 1J 1J 1J 1J 1J 




If a/ = aB2, then the between-subject variance components a/ + a/ and aB2 + as2 are 
respectively equal as well. 








D is a linear combination of dependent X2 variable. Thus, an approximate z-statistic will be used 
to derive p-values for the test ofHo: OA2 = 0B2. Hence, the p-value for testing the between-subject 
variability is 
p = 2(1 - 'P(Z)), 
where 'P is the standard normal distribution function. 
The p-value for testing the within-subject variability (Ho: 0/ = OfJ2) is from a F-test. Let 
A2 C2 °E 33 F = 
then F - F(n, n). Hence the within-subject p-value is 
p = F(n, n) (r), 
where r = max(F, IfF). 
Since OS2 + OA2 =(OS2 + OA2 + 0/12) - 0/12 = Oil - 0 33 is the between-subject variance component 
for Treatment A, 0/ + OA2 may be estimated by (C II - C33)/n. Similarly, the between-subject 
variance component for Treatment B may be estimated by (C22 - C44)/n. 
The within-subject variance for Treatment A is estimated by 2C3/n, and the within-subject 
variance for Treatment B is estimated by 2C4in. 
If it is desired to estimate the coefficient of variation of the variance components, the problem 
may be simplified by taking the natural log of each value and compute variance components of 
transformed values. The square root of variance components when multiplied by 100 yield an 
estimate of the corresponding coefficients of variation of the untransformed values. That is 
SD 
100~Var(lnX) ::= 100_x. 
~x 
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3. Evaluation of Individual Bioequivalence 
It was further desired to determine whether the average effect of the treatments may be applied to 
the population as a whole or whether each subject had his own unique difference between the 
treatments. If OA2 = OB2 = 0 and 0/ = 0T]2 then the treatment effect difference "CA - "CB was equally 
valid for each individual subject. 
Define 
Then 
DTC = ZSI - ZS2 for sequence 1, and 
DTC = W SI - W S2 for sequence 2. 
E(DTC) = "C A - "CB + (1t 1 - 1t2 - 1t3 + 1t4)12, for sequence 1 subjects, and 
E(DTC) = "C A - "CB - (1t I - 1t2 - 1t3 + 1t4)12, for sequence 2 subjects, and 
Var(DTd = OA2 + OB2 +0/12 + 0T]212, for both sequences. 
Remember that treatment A was a Capsule and B was a Tablet. 
Furthermore, define 
Then 
Dcc = 2ZS3 for sequence 1, and 
Dcc = 2W S3 for sequence 2. 
E(Dcd = 1t1 - 1t4 , for sequence 1 subjects, and 
E(Dcd = 1t2 - 1t3 , for sequence 2 subjects, and 
Var(Dcd = 0/, for both sequences. 
Furthermore, define 
Then r = 1 when 0/ = OB2 = 0 and 0€2 = 0T]2. The parameter maybe used as an index of the extent 
to which average difference between the capsule and the tablet may be applied to individual 
subjects. Values of r closed to 1 indicate good applicability of the population average difference 
to individual subjects. Large values of r indicate that each patient has his own rule. 













Rlr - F(n, n). 
- (1) 1" - (Z) 
DTe --~ DTe ' DTe 
Nl -1 seq=l 
_1-L DTC' 
N z -1 seq=Z 




Since Pre Rlr> F(n,n)(0.05)) = 0.95, the upper 95% confidence limit for r can be calculated by 
RIF(n, n)(0.05). 
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4. Examples 
To illustrate our approach, 4 samples were randomly generated using the model described in 
Chapter 2. Each sample was generated using a different set of parameters. There are 24 subjects 
in a group, 12 in each sequence. The data was log transformed before analysis. Tables 1 and 2 
give the variance component estimates and p-values from different set of parameters. Table 3 
gives the test results for individual bioequivalence. The STD of the transformed data is 
essentially the CY of the original data. For a subject, the interclass correlation is calculated as 
In the first sample, the parameters are set as follows: 
as = 0.30, aA = 0, aB = 0.40, a€ = 0.05, and aT) = 0.10. Therefore the interclass correlation = 
0.58. 
The within-subject %CY for tablet = 100xaT) =10. The within-subject %CY for capsule = 
100xa€ = 5. The estimates for the %CY are 11.25 and 5.46 respectively. It turn out that the p-
value for testing the equality of the two %CY is 0.001 (Table 1). In this sample, the between-
subject %CY for tablet = 100x(a/ + a B2y/2 = 50, and the between-subject %CY for capsule = 
100x(as2 + aA2)'h = 30, The estimates for the %CY are 47.31 and 29.55 respectively. P-value for 
testing the equality of the two %CY is 0.035 (Table 2). 
Also from this sample, the individual bioequivalence index r = 66.50. Its estimate is 49.16 and 
the p-value for testing r = 1 is <0.001 (Table 3). 
As seen from Tables 1,2 and 3, for all these four samples the test essentially give the correct 
conclusion. 
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Table 1. Within-subject variability of pharmacokinetic parameters by formulation 
Sample Information Interclass Tablet Capsule P-Value 
Correlation Within %CV Within %CV Within 
1 Parameters 0.580 10 5 
Estimates 11.25 5.46 0.001 
2 Parameters 0.364 30 30 
Estimates 33.75 32.76 0.889 
3 Parameters 0.900 10 10 
Estimates 11.25 10.92 0.889 
4 Parameters 0.500 10 10 
Estimates 11.25 10.92 0.889 
Table 2. Between-subject variability of pharmacokinetic parameters by formulation 
Interclass Tablet Capsule P-Value 
Sample Information Correlation Between %CV Between %CV Between 
1 Parameters 0.580 50 30 
Estimates 47.31 29.55 0.035 
2 Parameters 0.364 50 30 
Estimates 46.34 25.63 0.077 
3 Parameters 0.900 30 30 
Estimates 29.39 29.43 0.986 
4 Parameters 0.500 30 30 
Estimates 28.50 28.06 0.940 
Table 3. Analysis of individual bioequivalence between formulation 
Population Sample 95% Upper P-Value for 
Interclass Individual Individual Confidence Testing 
Sample Correlation Bioequivalence Bioequivalence Band for Different 
Index Index Index from 1 
1 0.580 66.50 49.16 100.7 <0.001 
2 0.364 2.78 1.98 4.06 0.058 
3 0.900 1.00 0.73 1.49 0.769 
4 0.500 9.00 8.13 16.65 <0.001 
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5. Summary 
In order to compare within- and between-subject variance components in a cross-over design, it 
is necessary to define a new mixed linear model for a pharmacokinetic crossover trial. Terms 
have to be added to the model for the subject by treatment interaction for each dosage form 
investigated. Error terms in the model also have to differ between dosage forms. 
Comparisons of means and within-subject variance components may be done in a straight 
forward manner. A test of the difference between the between-subject components is developed 
using a Z-test and an estimate of the covariance of the between-subject variance components. 
The size of the variance of the within-subject, between treatment difference relative to the 
variance of the within-subject, within standard dosage form difference provides an index of the 
extent of the appropriateness of using the population average relative bioavailability as a measure 
of each individual subject's relative bioavailability. This index provides a measure of the 
relative size of the subject by treatment interactions. It also has a scaled F-distribution which is 
very easy to work with in applications. 
Examples presented show that in cases where the size of within- and between-subject CV may be 
of concern, differences can be found with moderate size samples. Examples presented also show 
that it may be possible to have equal between and within-subject CV's for 2 dosage forms, but at 
the same time the use of the average bioavailability is inappropriate because the subject by 
dosage form interactions are relatively large compared to the within-subject CV. 
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